Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is the issuer named in an amended Schedule 13G reporting beneficial ownership of its common stock. For the September 30, 2026 event date, Deerfield Management Company, L.P. and James E. Flynn each reported 3,138,167 shares, or 3.91%, with shared voting and dispositive power and no sole voting or dispositive power. The two underlying funds, Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., reported 1,569,083 and 1,569,084 shares, respectively, each representing 1.96%. The figures overlap because the larger reported interests comprise shares held by those funds.
Key Figures
Reported beneficial ownership:3,138,167 sharesPercent of class:3.91%Deerfield Partners, L.P. shares:1,569,083 shares+1 more
4 metrics
Reported beneficial ownership3,138,167 sharesReported by Deerfield Management Company, L.P. and James E. Flynn; September 30, 2026 event date
Percent of class3.91%Reported by Deerfield Management Company, L.P. and James E. Flynn
Deerfield Partners, L.P. shares1,569,083 sharesReported beneficial ownership; 1.96% of the class
Deerfield Private Design Fund V, L.P. shares1,569,084 sharesReported beneficial ownership; 1.96% of the class
Key Terms
Aggregate Amount Beneficially Owned, Shared Voting Power, Shared Dispositive Power
3 terms
Aggregate Amount Beneficially Ownedregulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Shared Voting Powerregulatory
"Shared Voting Power 1,569,083"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 1,569,083"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many BBOT shares did Deerfield report owning?
Deerfield Management Company, L.P. and James E. Flynn each reported beneficial ownership of 3,138,167 BBOT shares, or 3.91%, for the September 30, 2026 event date. The reported interests comprise shares held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.
Who had voting and dispositive power over the reported BBOT shares?
The reporting persons disclosed shared voting and dispositive power over their reported shares and zero sole voting or dispositive power. Deerfield Management Company, L.P. and James E. Flynn each reported shared power over 3,138,167 shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
BridgeBio Oncology Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
107924102
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
Deerfield Mgmt, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,569,083.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,569,083.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,569,083.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.96 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
Deerfield Mgmt V, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,569,084.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,569,084.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,569,084.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.96 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of common stock held by Deerfield Private Design Fund V, L.P., of which Deerfield Mgmt V, L.P. is the general partner.
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
Deerfield Partners, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,569,083.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,569,083.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,569,083.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.96 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
Deerfield Private Design Fund V, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,569,084.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,569,084.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,569,084.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.96 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
Deerfield Management Company, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,138,167.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,138,167.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,138,167.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.91 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., of which Deerfield Management Company, L.P. is the investment advisor.
SCHEDULE 13G
CUSIP Number(s):
107924102
1
Names of Reporting Persons
James E. Flynn
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,138,167.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,138,167.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,138,167.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.91 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BridgeBio Oncology Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
256 E. Grand Avenue, Suite 104, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.
(b)
Address or principal business office or, if none, residence:
James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
(c)
Citizenship:
Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P. - Delaware limited partnerships;
James E. Flynn - United States citizen
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
107924102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit B
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Deerfield Mgmt, L.P.
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
Deerfield Mgmt V, L.P.
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
Deerfield Partners, L.P.
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
Deerfield Private Design Fund V, L.P.
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
Deerfield Management Company, L.P.
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
James E. Flynn
Signature:
/s/ Jonathan Isler
Name/Title:
Jonathan Isler, Attorney-In-Fact
Date:
11/13/2026
Exhibit Information
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.